CLINICAL TRIALS PROFILE FOR CYPROHEPTADINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for Cyproheptadine Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00066248 ↗ | Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment | Completed | National Cancer Institute (NCI) | Phase 2 | 2003-06-01 | RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer. PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in improving appetite and preventing weight loss in children with cachexia caused by cancer or cancer treatment. |
| NCT00066248 ↗ | Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment | Completed | University of South Florida | Phase 2 | 2003-06-01 | RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer. PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in improving appetite and preventing weight loss in children with cachexia caused by cancer or cancer treatment. |
| NCT00108420 ↗ | Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance | Completed | US Department of Veterans Affairs | Phase 4 | 2003-10-01 | The purpose of this study is to determine whether prazosin will reduce the incidence of nightmares, sleep disturbance, and overall symptoms in combat trauma-exposed individuals with PTSD. |
| NCT00108420 ↗ | Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance | Completed | VA Office of Research and Development | Phase 4 | 2003-10-01 | The purpose of this study is to determine whether prazosin will reduce the incidence of nightmares, sleep disturbance, and overall symptoms in combat trauma-exposed individuals with PTSD. |
| NCT00286988 ↗ | Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children | Terminated | Ortho-McNeil Neurologics, Inc. | Phase 4 | 2006-03-01 | The purpose of this study is to assess the effectiveness, tolerability and safety of oral topiramate for the preventative management of Cyclic Vomiting Syndrome. It is believed that topiramate will decrease the frequency, duration and severity of attacks experienced by children and adolescents with Cyclic Vomiting Syndrome. |
| NCT00286988 ↗ | Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children | Terminated | Monarch Medical Research | Phase 4 | 2006-03-01 | The purpose of this study is to assess the effectiveness, tolerability and safety of oral topiramate for the preventative management of Cyclic Vomiting Syndrome. It is believed that topiramate will decrease the frequency, duration and severity of attacks experienced by children and adolescents with Cyclic Vomiting Syndrome. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Cyproheptadine Hydrochloride
Condition Name
Clinical Trial Locations for Cyproheptadine Hydrochloride
Trials by Country
Clinical Trial Progress for Cyproheptadine Hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for Cyproheptadine Hydrochloride
Sponsor Name
